Clinical trials referenced in this document:
Documents that mention this clinical trial
Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients
Funding for this research was provided by:
hospices civils de lyon
Received: 6 September 2021
Accepted: 13 January 2022
First Online: 5 March 2022
Change Date: 1 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13613-022-01007-7
: This project was part of an ongoing prospective observational clinical study (RICO, REA-IMMUNO-COVID) performed in line with the principles of the Declaration of Helsinki. It was approved by ethics committee (Comité de Protection des Personnes Ile de France 1-N°IRB / IORG #: IORG0009918) under agreement number 2020-A01079-30. This clinical study was registered at ClinicalTrials.gov (NCT04392401). The committee waived the need for written informed consent because the study was observational, with a low risk to patients, and no specific procedure, other than routine blood sampling, was required. Oral information and non-opposition to inclusion in the study were mandatory and were systematically obtained before any blood sample was drawn. This was recorded in patients’ clinical files. If a patient was unable to consent directly, non-opposition was obtained from the patient’s legally authorized representative and reconfirmed from the patient at the earliest opportunity.
: All authors have read the manuscript and have consented for its publication.
: The authors declare no competing financial interests in relation to the work. MAC, KBP and MM are bioMérieux’s employees. This private company had no role in the study design, result analysis and decision to publish this study.